Warrant Exercise

RNS Number : 5687S
Belluscura PLC
15 July 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company" or "Group")

Exercise of Warrants and Total Voting Rights

 

Warrant Exercise

 

LONDON, U.K. AND PLANO, TX, U.S.   (15 July 2022).  Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 500,000 shares in the share capital of Belluscura ("the Warrant Shares") at exercise prices of 45 pence. The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of 235,000.05.

 

The Warrant Shares were allotted on 14 July 2022. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or around 21 July 2022. These shares will rank pari passu with the ordinary shares of the Company in issue.

 

Total voting rights

 

The Company's total issued capital, after the issue of the Warrant Shares, will be 121,794,268 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP Communications

Anthony Dyer, Chief Financial Officer


 


SPARK Advisory Partners Ltd (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin


 


Dowgate Capital Ltd (Broker & Bookrunner)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers


 


MHP Communications (Media & Investor Relations)

 Telephone: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew Taylor  

or belluscura@mhpc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCRIMRTMTJBBAT

Companies

Belluscura (BELL)
UK 100

Latest directors dealings